Tag: Policy

  • STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine

    STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine

    By Ed Silverman

    Oct. 14, 2026

    Pharmalot Columnist, Senior Writer

    Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

    European Union antitrust regulators accepted concessions from Sanofi to settle an investigation into an allegedly “misleading” campaign that disparaged the only rival flu vaccine recommended for vulnerable patients at risk for developing the illness. In doing so, the company avoided being fined.

    The European Commission had suggested that Sanofi portrayed the Fluad vaccine marketed by CSL Seqirus as inferior to its own Efluelda vaccine in a communication campaign that primarily targeted health care professionals in Germany and France. Sanofi holds a dominant position in both countries, according to the EC.

    To resolve the probe, Sanofi committed to a corrective communication campaign rectifying its “possible disparaging behavior” and to refrain from such behavior in the future, according to Teresa Riberta, the European Commission executive vice president for Clean, Just and Competitive Transition. The agreement is legally binding.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • STAT+: Lobbyists and trade groups fight to shape how states regulate medical AI

    STAT+: Lobbyists and trade groups fight to shape how states regulate medical AI

    Influential lobbying groups for doctors and hospitals, a health insurer, technology companies, and representatives from state governments met behind closed doors in Washington, D.C., in early October to develop guidelines for how to regulate artificial intelligence in the practice of medicine.

    Executives from the American Medical Association, American Hospital Association, artificial intelligence giant Anthropic, and insurer Elevance Health are part of a 22 member AI workgroup convened by the Federation of State Medical Boards, or FSMB, a national organization that advocates for state boards. A spokesman said the workgroup “was built to balance expertise across medical regulation, AI development, care delivery, academic medicine, state AI policy, and patient safety,” and that its recommendations would be open for feedback before being formally adopted.

    The discussions within workgroup meetings are being kept confidential, but the goal is to draft guidelines to aid local medical boards, with “particular attention … to AI tools that perform clinical functions with limited or no direct physician supervision,” Humayun Chaudhry, the FSMB’s president and CEO, told STAT. A draft of the recommendations could be made public in “weeks to months,” said Chaudhry. They could ultimately form the basis of legislation in states, which individually regulate medical licensure and the practice of medicine.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds

    By Ed Silverman

    Oct. 13, 2026

    Pharmalot Columnist, Senior Writer

    Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

    Nearly 40% of Food and Drug Administration advisory committee meetings held over a recent 20-year period included either a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies, according to a new analysis. And for several committees, the number of such reps exceeded 50%.

    In addition, more than one in 10 advisory committee meetings included a rep who was affiliated with an organization that received funding from the drugmaker whose medicine was being reviewed by the committees. Yet most of these organizational ties were not disclosed at the meetings, raising questions about voting behavior.

    The analysis, which was published in Health Affairs Scholar, noted the FDA has well-established conflict-of-interest policies for its scientific advisory committee members, but policies concerning patient and consumer reps are not as well developed, especially concerning industry funding of advocacy groups whose members appear on committees.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds

    STAT+: Many patient, consumer reps on FDA advisory panels have ties to groups funded by pharma, analysis finds

    By Ed Silverman

    Oct. 13, 2026

    Pharmalot Columnist, Senior Writer

    Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

    Nearly 40% of Food and Drug Administration advisory committee meetings held over a recent 20-year period included either a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies, according to a new analysis. And for several committees, the number of such reps exceeded 50%.

    In addition, more than one in 10 advisory committee meetings included a rep who was affiliated with an organization that received funding from the drugmaker whose medicine was being reviewed by the committees. Yet most of these organizational ties were not disclosed at the meetings, raising questions about voting behavior.

    The analysis, which was published in Health Affairs Scholar, noted the FDA has well-established conflict-of-interest policies for its scientific advisory committee members, but policies concerning patient and consumer reps are not as well developed, especially concerning industry funding of advocacy groups whose members appear on committees.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • Medicare Policy Shouldn’t Be Made in the Shadows

    Medicare Policy Shouldn’t Be Made in the Shadows

    As a rheumatologist, I treat rheumatoid arthritis (RA) and other complex autoimmune diseases. If you have or happen to develop one of these diseases, I am thankful that science has delivered amazingly effective targeted therapeutics and biologics in recent decades. While highly effective, these treatments come with a high economic cost, so I have grown accustomed to daily battles with commercial insurance plans to get working-age patients the treatments they need. While horror stories abound regarding commercial insurers, Medicare has traditionally been a more predictable partner for my older patients. Medicare reimbursement is low — an issue worthy of a separate commentary piece — but comes on time, typically without the hassle and administrative delays of prior authorizations, assuming we use our therapeutics within FDA-approved dosing and indications.

    On top of these existing challenges here in the Midwest, providers recently won a battle we did not expect to have to fight with a Medicare administrative contractor (MAC). The story deserves scrutiny from legislators and regulators nationwide. 

    Medicare beneficiaries rightly assume, as have I, that policy spells out the services they are entitled to receive. Lawmakers in Congress establish patients’ benefits in law, while the Centers for Medicare & Medicaid Services (CMS) develops the national rules and policies to implement them. MACs fit into this process by administering those rules regionally (with some discretion), but they are not supposed to privately create new substantive conditions of payment.

    Recently, the MAC overseeing Kentucky and Ohio began auditing and denying claims for intravenous Orencia, a biologic drug used to treat RA, citing a “lack of medical necessity.” The policy affected more than a hundred patients who had mostly been on Orencia for a decade or more. These patients were forced to stop or delay treatment or switch therapies, which resulted in serious RA flares. MAC administrators had decided that most patients on intravenous Orencia, covered under Medicare Part B, should instead receive subcutaneous Orencia, covered under Medicare Part D and often at substantially higher out-of-pocket cost. 

    The decision was made without a formal notice-and-comment process. In fact, this requirement does not even appear in the Medicare guidance cited for this decision. Worst of all, it effectively forced dozens of patients off a life-changing therapy.

    Thanks to outreach from clinicians, national advocacy organizations, angry patients, and congressional representatives, this policy was walked back. Or at least, we think so. There was no announcement of a reversal. Instead, the MAC covering Kentucky and Ohio quietly revised a fact sheet on its website, removing language that preferred subcutaneous over intravenous dosing. 

    This whiplash has been devastating to my own small clinic, however, as the MAC continues to withhold the equivalent of roughly three payrolls’ worth of payments for treatments we rendered in good faith during this period. They have also not answered repeated inquiries about whether denials issued under the now-removed standard will be reversed. 

    This situation exposed several problems that need to be addressed before this happens to other MACs, Medicare beneficiaries and clinicians:

    1. The current system allowed one medical director’s opinion to acquire the force of Medicare policy without an effective check. This violates the Supreme Court’s decision in Azar v. Allina, which limits the government’s ability to create substantive Medicare payment standards through informal guidance. Yet it still took months of work, worry, and countless hours distracted from providing clinical care to get the issue elevated to a level where the policy was reconsidered. 

    2. There is inadequate accountability and little transparency within MAC operations. After an initial call with the MAC medical director to raise this issue, we went for weeks with response and no clue as to where our appeal stood. Providers didn’t know how to “correctly” care for our affected patients. When the disputed language did quietly disappear from the fact sheet, there was no public explanation, formal announcement, or directive regarding claims already denied. 

    3. There is no clearly identified chain of command to move a critical issue of patient harm from a regional MAC to CMS. As an experienced advocate, I leveraged my relationship with my congressional representative and the American College of Rheumatology to elevate this issue to CMS, but what if I hadn’t had those relationships? Our system should not require physicians to become experts in Medicare law and policy just to ensure the Medicare system follows its own rules.

    Medicare beneficiaries deserve better. While in this case we’ve been able to protect access to intravenous Orencia, this experience exposed flaws that extend far beyond one drug or one MAC contractor. We should all be concerned that MACs are increasingly making unilateral decisions that negatively impact patient access. Medicare policy should be transparent and include appropriate notice and stakeholder input. And when a contractor gets it wrong, there should be a clear and rapid way to stop the harm to patients, their relationship with their doctor and the doctor’s practice. A patient’s access to Medicare-covered care should never depend on whether their physician can find someone in Washington willing to intervene. Something must change.

    Author bio:

    Dr. Chris Phillips is an American College of Rheumatology leading rheumatologist and owner of Paducah Rheumatology.

    Photo: Stas_V, Getty Images

  • Pediatric Innovation Isn’t a Small-Market Problem, It’s an Incentive Problem

    Pediatric Innovation Isn’t a Small-Market Problem, It’s an Incentive Problem

    pediatric kids children

    The case for investing in children’s health should be self-evident. As a society we have a responsibility to invest in the next generation, and few investments carry greater long-term benefit than helping children reach their healthiest possible futures.

    When we diagnose and treat conditions early, we do more than improve a child’s health in the moment. We are altering the trajectory of their entire life: development of their personal confidence, resilience, mental wellbeing, learning capacity, and in many cases, also reducing decades of downstream public and private healthcare costs.

    Yet, pediatric innovation remains chronically and systemically undervalued in healthcare.

    That is not because the market for pediatric healthcare is small, it is because the incentives are misaligned. The cost of treating a child’s condition is incurred immediately. However, when early pediatric interventions are effective, their benefits often compound over decades.

    No single stakeholder is incentivized to properly and accurately consider the full return on early pediatric interventions and support their adoption. The average tenure of a person staying on the same health plan is two to three years. As a result, private insurers are focused on cost savings that will be realized within that time frame, which for pediatric treatments especially, may only represent a small proportion of the overall benefit.

    On the public insurance side, children are largely covered by Medicaid, and while pediatric health is a central tenet of Medicaid’s mission, the program is too often hamstrung by its structure. Unlike Medicare, which is entirely financed at the federal level, Medicaid is jointly financed between the federal government and each individual state. The program is often left underfunded, as its budget is subject to annual appropriations decisions by state legislators who have limited fiscal flexibility. Priorities are constantly changing, making long-term planning next to impossible for Medicaid decision makers.

    That misalignment has consequences well before a new technology ever reaches a payer’s desk. When long-term pediatric outcomes are undervalued, the ripple effect moves backward through the entire innovation pipeline, shaping what gets funded, what gets studied, and what ultimately reaches patients.

    Investors, wary of uncertain reimbursement and lower near-term returns, often direct capital toward adult indications with clearer paths to market. Drug and device developers may follow the same logic, deprioritize pediatric programs or skip pediatric studies. The result is a self-reinforcing cycle: limited investment leads to fewer pediatric success stories, which then reinforces the false perception that pediatric markets are too small or too risky to justify meaningful investment.

    This is why pediatric innovation in healthcare must be evaluated differently.

    Payers should require robust clinical evidence to make responsible coverage decisions. But the decision making framework for pediatric products should reflect the unique realities of childhood conditions: the value of early intervention, the long-term costs and consequences of undertreatment, and the potential for a therapy to alter a child’s life path before preventable challenges become permanent ones.

    Policy leaders should also examine whether existing pediatric coverage pathways are actually keeping pace with modern innovation. In theory, we already have a powerful mechanism for this: the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit. Under federal law, EPSDT mandates that Medicaid-enrolled children receive all medically necessary services to correct or ameliorate important pediatric conditions, regardless of whether those services are explicitly covered in a state’s standard plan. It is a visionary policy designed to ensure that no child is left behind by the structural limitations of our healthcare system. In practice, awareness of the EPSDT benefit among Medicaid beneficiaries is low, and Medicaid plans need to do more to streamline the approval process for EPSDT-covered technologies.

    Investing in pediatric care is not simply a moral imperative. It is one of the most practical long-term investments the healthcare system can make.

    The question is not whether children’s health is worth the investment, that answer is self-evident. The real question is whether our healthcare ecosystem has the foresight to correct these incentive structures before another generation of children bear the cost of our delay.

    Photo: Suriyapong Thongsawang, Getty Images

    Scott Xiao

    Scott Xiao is the co-founder and CEO of Luminopia, a therapeutics company developing software-based interventions at the intersection of ophthalmology and neuroscience. Luminopia’s lead product is a novel FDA-cleared prescription digital therapeutic for amblyopia, the leading cause of vision loss in children, affecting approximately 1 in every 30 children. Scott founded Luminopia after leaving Harvard University at age 17, inspired by a classmate’s experience with amblyopia and the limitations of traditional treatment. He has led the company from early development through clinical validation, regulatory clearance and national commercialization, with the therapy now prescribed to more than 12,000 patients by 1,300+ providers at 600+ top eye institutes, children’s hospitals and private practices. Under his leadership, Luminopia became the first FDA-cleared virtual reality–based treatment for any medical condition. Scott has also spearheaded Luminopia’s real-world evidence strategy, including the development of the PUPiL Registry, which has been instrumental in securing both FDA label expansion and major payer coverage decisions. Scott has been recognized on Forbes 30 Under 30 list in Healthcare, MIT Technology Review Innovators Under 35, and Modern Healthcare’s 40 Under 40. Luminopia was also named one of TIME’s Best Inventions of 2023. Scott is a strong advocate for the role of technology in improving patient engagement and outcomes and is focused on expanding Luminopia’s pipeline to address additional neuro-visual conditions, including strabismus and vision loss following stroke or traumatic brain injury.

    This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.

  • Are Hospital Operating Rooms Ready For FDA’s Expectations for Surgical Robots?

    Are Hospital Operating Rooms Ready For FDA’s Expectations for Surgical Robots?

    Robotics are increasingly being incorporated into today’s complex surgeries, and their capabilities are quickly expanding as they take on new tasks and higher levels of autonomy. The FDA recently published draft guidance on pre-market testing for robotically-assisted surgical devices, raising timely discussion around whether hospital infrastructures are capable of supporting increasingly complex systems. 

    It describes how robotic surgical devices should be tested prior to clinical use, covering everything from the robot’s movements to the design of its software, its reliability and accuracy, its cybersecurity measures, safety and sterility, how it visualizes patient images, and how it interfaces with the surgical team. The guidance is aimed at manufacturers and is currently nonbinding; it is open for comment until November 24. 

    As surgical technology becomes increasingly connected, the FDA’s guidance asks manufacturers to consider how different software functions within a single operating room interact. This raises a critical question for hospitals: as surgical robots become more sophisticated, what must the operating rooms around them have to successfully integrate the new technology? 

    Dr. Nadine Hachach-Haram, a surgeon and the founder and CEO of Proximie, argues that the answer lies in understanding the operating room as a connected clinical ecosystem. 

    “What stands out to me in the FDA’s guidance is that it treats the robot as part of a much wider clinical system,”  Hachach-Haram said. “It looks beyond the device itself to the software, connectivity, training and the environment in which it will actually be used. That matters because, as a surgeon, you quickly see that even very advanced technology has to work within the reality of the operating room.” 

    Proximie, headquartered in London, is a health technology company whose platform is designed to connect operating room devices and support intra-operative video and data capture. The company says its software is used by more than 700 hospitals worldwide. 

    Hachach-Haram asserts that it’s important for manufacturers to assess whether the addition of more complex capabilities may impact the performance of a new robotic device, a consideration which the FDA guidance also underscores. 

    “A great robot should still be a great robot once the video and data sit alongside it, not a lesser robot with a video system attached,” said Hachach-Haram. 

    The FDA guidance also addresses cybersecurity, a subject that’s top-of-mind for today’s healthcare leaders. 

    The guidance warned:

    “Failure to maintain cybersecurity can result in risks such as compromised device functionality, loss of device availability, loss of data (medical or personal) availability and/or integrity, or exposure of other connected devices or networks to security threats. This in turn may have the potential to result in patient injury.”

    Human factors are another focus, with the FDA emphasizing that testing should be conducted in realistic contexts to accurately assess performance within real-world operating room conditions. 

    As surgical robots continue to evolve, the guidance asks manufacturers to prove that these new technologies work smoothly as part of today’s complex human-and-machine operating team. 

    Photo: PhonlamaiPhoto, Getty Images

  • STAT+: Biotech companies are struggling to navigate Trump’s new tariffs

    STAT+: Biotech companies are struggling to navigate Trump’s new tariffs

    WASHINGTON — A broad tariff on imported pharmaceuticals took effect at the end of September, and some biopharma companies and the industry group that represents them say many are being left in the dark on how to get exemptions. 

    The Trump administration announced a 100% section 232 tariff in April, impacting imports of patented drugs and their active ingredients. At the time, the White House offered a number of pathways for companies to reduce their tariff burden, including striking a most-favored nation deal to sell drugs in the U.S. at similar prices to other wealthy countries or agreeing to bring production to the U.S.

    Companies that made MFN agreements would have had start paying tariff costs in July, but now aren’t on the hook for payment until early 2029, per their agreements. That exempts many of the biggest U.S. drugmakers, while leaving smaller biotech firms to face the levies.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • STAT+: Justice Department targets drugmakers in new directive on combating white-collar fraud

    STAT+: Justice Department targets drugmakers in new directive on combating white-collar fraud

    By Ed Silverman

    Oct. 7, 2026

    Pharmalot Columnist, Senior Writer

    Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

    In a warning to life sciences companies, the Department of Justice last week issued a new directive for combating fraud that made a point of noting the agency will pursue violations of a federal law that tightly regulates the pharmaceutical industry.

    Typically, the agency has pursued health fraud cases centered on providers, clinics, home health agencies, and hospices. By expressly including the Federal Food, Drug, and Cosmetic Act in the directive, the National Fraud Enforcement Division appears to be placing drug and device makers, among others, more clearly in its crosshairs.

    “This is a subtle but significant expansion of their jurisdiction,” said Kevin Lowell, a member of the Miller & Chevalier law firm, who spent a decade at the DOJ, where he most recently had been a deputy chief in the National Fraud Enforcement Division’s health care fraud section.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+

    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

  • FTC Sends Warning Letters to 24 Healthcare Organizations Over Price Transparency

    FTC Sends Warning Letters to 24 Healthcare Organizations Over Price Transparency

    The Federal Trade Commission sent warning letters to 24 of the “nation’s largest” healthcare services companies, citing concerns that they may be failing to provide transparent price information.

    The letters were signed by FTC Chairman Andrew N. Ferguson. The agency did not disclose which organizations it sent the letters to.

    It notes in the letter that Section 5 of the FTC Act requires these organizations to provide patients with “timely, accurate, and complete pricing for healthcare services, especially for non-emergency services that are scheduled in advance.” The agency urged the organizations to conduct a review of their pricing practices and make changes if they find they’re in violation of the FTC Act. 

    The letter also stated that price transparency is a major priority of the FTC across several sectors, including rental housing, hotels and grocery delivery services. Consumers can’t compare offerings and make informed decisions without price transparency, the letter said.

    “Price transparency is particularly critical in the hospital and healthcare setting because healthcare is often one of the most significant and financially burdensome costs consumers face,” Ferguson wrote in the letter. “Patients frequently must invest substantial time and effort to travel for in‑person visits, making it even more important that they understand costs upfront before committing to care. Moreover, hospitals and healthcare facilities can charge dramatically different prices for the same services, leaving consumers vulnerable to wide and often unexpected cost discrepancies.”

    CMS requires hospitals to publicly disclose pricing information for healthcare services through machine-readable files and consumer-friendly pricing information. They also must provide uninsured and self-pay patients with good-faith estimates of expected charges before scheduled care. However, the FTC stated that complying with CMS price transparency requirements doesn’t necessarily mean a healthcare provider is complying with the FTC Act, which may impose additional requirements. 

    The letter notes that the price of healthcare services is a “material term,” meaning “clear and conspicuous disclosures” are needed so consumers are not deceived.

    “Accordingly, failing to disclose the price of a healthcare service may be deceptive if it is likely to mislead consumers acting reasonably under the circumstances,” Ferguson wrote. “Even when some price terms are disclosed, disclosures may be deceptive when they are incomplete — such as when they omit certain charges like physician fees or facility fees, or cover only a portion of the expected care — because consumers may reasonably believe they have been provided the total cost of care. Likewise, inaccurate disclosures mislead consumers and cause substantial harm.”

    The FTC said the letters do not conclude that the recipients violated the FTC Act. 

    Photo: Oleksandr Hruts, Getty Images